The -13.88% Decline of Transmedics Group Inc’s (TMDX) Stock in the Past Quarter

In the past week, TMDX stock has gone down by -1.57%, with a monthly decline of -5.79% and a quarterly surge of 4.53%. The volatility ratio for the week is 5.66%, and the volatility levels for the last 30 days are 5.46% for Transmedics Group Inc The simple moving average for the past 20 days is 3.20% for TMDX’s stock, with a 34.73% simple moving average for the past 200 days.

Is It Worth Investing in Transmedics Group Inc (NASDAQ: TMDX) Right Now?

The price-to-earnings ratio for Transmedics Group Inc (NASDAQ: TMDX) is 4397.76x, which is above its average ratio. Moreover, the 36-month beta value for TMDX is 1.99. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for TMDX is 32.23M and currently, short sellers hold a 17.06% of that float. On October 01, 2024, TMDX’s average trading volume was 850.13K shares.

TMDX) stock’s latest price update

Transmedics Group Inc (NASDAQ: TMDX)’s stock price has decreased by -1.34 compared to its previous closing price of 159.14. However, the company has seen a -1.57% decrease in its stock price over the last five trading sessions. zacks.com reported 2024-09-30 that TransMedics (TMDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Analysts’ Opinion of TMDX

Many brokerage firms have already submitted their reports for TMDX stocks, with Robert W. Baird repeating the rating for TMDX by listing it as a “Outperform.” The predicted price for TMDX in the upcoming period, according to Robert W. Baird is $200 based on the research report published on September 24, 2024 of the current year 2024.

Needham, on the other hand, stated in their research note that they expect to see TMDX reach a price target of $208. The rating they have provided for TMDX stocks is “Buy” according to the report published on August 21st, 2024.

Cantor Fitzgerald gave a rating of “Overweight” to TMDX, setting the target price at $161 in the report published on June 06th of the current year.

TMDX Trading at 0.74% from the 50-Day Moving Average

After a stumble in the market that brought TMDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.48% of loss for the given period.

Volatility was left at 5.46%, however, over the last 30 days, the volatility rate increased by 5.66%, as shares sank -6.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.66% upper at present.

During the last 5 trading sessions, TMDX fell by -1.57%, which changed the moving average for the period of 200-days by +114.51% in comparison to the 20-day moving average, which settled at $151.58. In addition, Transmedics Group Inc saw 98.91% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at TMDX starting from Hassanein Waleed H, who sale 8,625 shares at the price of $153.42 back on Sep 16 ’24. After this action, Hassanein Waleed H now owns 61,643 shares of Transmedics Group Inc, valued at $1,323,210 using the latest closing price.

Khayal Tamer I, the Chief Commercial Officer of Transmedics Group Inc, sale 2,960 shares at $159.60 during a trade that took place back on Sep 03 ’24, which means that Khayal Tamer I is holding 20,843 shares at $472,404 based on the most recent closing price.

Stock Fundamentals for TMDX

Current profitability levels for the company are sitting at:

  • -0.0 for the present operating margin
  • 0.61 for the gross margin

The net margin for Transmedics Group Inc stands at 0.01. The total capital return value is set at -0.0. Equity return is now at value 1.79, with 0.41 for asset returns.

Based on Transmedics Group Inc (TMDX), the company’s capital structure generated 0.73 points at debt to capital in total, while cash flow to debt ratio is standing at 0.05. The debt to equity ratio resting at 2.69. The interest coverage ratio of the stock is -0.06.

Currently, EBITDA for the company is 8.76 million with net debt to EBITDA at 9.1. When we switch over and look at the enterprise to sales, we see a ratio of 15.03. The receivables turnover for the company is 4.42for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.37.

Conclusion

To wrap up, the performance of Transmedics Group Inc (TMDX) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts